Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
SAN DIEGO, May 29, 2015 /PRNewswire/ -- Epic Sciences announced today that the company will present single... 
No comment yet.
Sign up to comment
|
Scoop.it!
Novel microfluidic devices give researchers new ways to count and sort single cells.
Gilbert C FAURE's insight:
These days, researchers are developing novel strategies to explore these possibilities. But they aren’t modifying traditional flow sorters to do so; they are downsizing their assays onto novel microfluidic devices. These miniaturized labs-on-a-chip enable investigators to enumerate and sort cells based on a wider range of physical and molecular properties than ever before, often without antibodies. The Scientist spoke with four researchers about the strategies they use for microfluidic cell sorting and evaluation.
|
Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations. Furthermore, the data show an association between CTC copy number alterations and phenotypic features, in terms of both cellular morphology and resistance to therapy. The study, titled "Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC)," was conducted in collaboration with clinical investigators at Memorial Sloan Kettering Cancer Center.